Abstract
Vasoactive intestinal peptide (VIP) is a widespread neurotransmitter whose physiological and pathophysiological actions are mediated by two receptor classes, VIP/pituitary adenylate cyclase-activating polypeptide (VPAC) 1 and VPAC2. VIP is a 28-amino acid peptide that is rapidly degraded and simplified; metabolically stable analogs are needed. In this study, we use information from studies of the VIP pharmacophore for VPAC1/VPAC2 to design nine simplified VIP analogs that could have high affinity and selectivity for each VPAC or that retained high affinity for both VPACs and were metabolically stable. From binding studies of their abilities to directly interact with hVPAC1 (T47D cells, hVPAC1-transfected cells) and hVPAC2 (Sup T1- and VPAC2-transfected cells) and to stimulate adenylate cyclase in each, two analogs [(Ala2,8,9,11,19,22,24,25,27,28)VIP and (Ala2,8,9,11,19,24–28)VIP] were found to have >2000- and >600-fold selectivity for hVPAC1. None of the nine analogs had hVPAC2 selectivity. However, two simplified analogs [(Ala2,8,9, 16,19,24)VIP and (Ala2,8,9,16,19,24,25)VIP] retained high affinity and potency for both hVPACs. 125I-[Ala2,8,9,16,19,24,25]VIP was much more metabolically stable than 125I-VIP. The availability of these simplified analogs of VIP, which are metabolically stable and have either hVPAC1 selectivity or retain high affinity for both hVPACs, should be useful for exploring the role of VPAC subtypes in mediating VIPs' actions as well as being useful therapeutically and for exploring the usefulness of VIP receptor imaging of tumors and VIP receptor-mediated tumor cytotoxicity.
Footnotes
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.088823.
-
ABBREVIATIONS: VIP, vasoactive intestinal peptide; VPAC, VIP-PACAP receptors (for nomenclature see Harmar et al., 1998); hVPAC1, human VPAC1 receptor subtype; hVPAC2, human VPAC2 receptor subtype; IBMX, 3-isobutyl-1-methyl xanthine; BSA, bovine serum albumin; PACAP, pituitary adenylate cyclase-activating peptide; DMEM, Dulbecco's modified Eagle's medium; HPLC, high-performance liquid chromatography; Ro 25-1553, Ac-His-Ser-Asp-Ala-Val-Phe-Thr-Glu-Asn-Tyr-Thr-Lys-Leu-Arg-Lys-Gln-Nle-Ala-Ala-Lys-cyclo[Lys-Tyr-Leu-Asn-Asp]-Leu-LysLysGly-Gy-Thr-NH2.
- Received April 28, 2005.
- Accepted June 28, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|